Paper Details

  1. Home
  2. Paper Details

Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study.

Author: AmanoKoichi, InoueHiroshi, IwahashiMitsuhiro, IzumiharaTomomaro, KanamonoToshihisa, KaryekarChetan S, MatsubaraTsukasa, NakanoTeruaki, TakeuchiTsutomu, TanakaTakaaki, UchimuraShoichi, YamazakiAkira

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Subcutaneous (SC) abatacept demonstrated comparable efficacy and safety to intravenous (IV) abatacept in Japanese patients with rheumatoid arthritis (RA).
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To evaluate efficacy and safety of subcutaneous (SC) and intravenous (IV) abatacept and background methotrexate (MTX) in Japanese patients with rheumatoid arthritis (RA) and inadequate response to MTX (MTX-IR). METHODS: Double-dummy, double-blind study (NCT01001832); 118 adults with ≥ 10...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3109/14397595.2014.881954

データ提供：米国国立医学図書館（NLM）

Abatacept: A New Frontier in Rheumatoid Arthritis Treatment

The search for effective and safe treatments for [rheumatoid arthritis (RA)] continues, with researchers constantly exploring new therapeutic options and delivery methods. This research investigates the efficacy and safety of subcutaneous (SC) and intravenous (IV) abatacept, a biologic therapy targeting the immune system, in Japanese patients with RA who have had an inadequate response to methotrexate. The authors compare the efficacy and safety of these two delivery routes, demonstrating the potential of SC abatacept as a convenient and effective treatment option for RA.

SC Abatacept: A Convenient and Effective Option for RA

The study found that SC abatacept achieved comparable efficacy to IV abatacept in improving RA symptoms and reducing disease activity, with similar safety profiles and low immunogenicity rates. This suggests that SC abatacept could be a more convenient and patient-friendly treatment option for RA, potentially improving adherence to therapy and enhancing overall patient well-being.

Optimizing RA Treatment for Patients

This research provides valuable insights into the effectiveness and safety of SC abatacept as a treatment option for RA. The study's findings suggest that SC abatacept could be a promising alternative to IV administration, offering greater convenience for patients and potentially improving long-term outcomes. This research encourages continued exploration of alternative delivery routes for biologic therapies, aiming to optimize treatment options for RA patients.

Dr.Camel's Conclusion

This research highlights the potential of SC abatacept as a convenient and effective treatment option for RA. Like a camel navigating a vast desert, RA patients often seek a treatment that provides relief and improves their quality of life. SC abatacept, with its comparable efficacy and safety to IV administration, emerges as a potential oasis in the desert of RA treatment, offering a more convenient and patient-friendly approach to managing this challenging condition.

Date :
  1. Date Completed 2015-06-25
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

24708204

DOI: Digital Object Identifier

10.3109/14397595.2014.881954

Related Literature

Article Analysis
・Effects of abatacept injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.